Plasma Resilience: Europe's Lifeline
Human plasma, a protein-rich liquid making up 55% of our blood, is crucial for developing therapies for various conditions, including rare inherited disorders and immunodeficiencies.
Despite its importance, Europe's plasma supply chain is vulnerable, relying on donations from over 12 million people annually, governed by EU and international safety standards.
- International Quality Plasma Program (IQPP)
- Plasma Protein Therapeutics Association (PPTA)
Nearly 40% of plasma used in European medicine production is imported from the United States, highlighting the need to strengthen the supply chain.
Each year, more than 12 million people across Europe donate plasma through a process governed by rigorous safety standards.
Author's summary: Europe relies heavily on human plasma donations.